Related Experiment Video
Updated: Nov 21, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Actinium-225 Prostate-specific Membrane Antigen Theranostics: Will α Beat β?
Nattakorn Dhiantravan1, Michael S Hofman1, Aravind S Ravi Kumar1
1Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Optimizing prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) depends on well-designed prospective trials. Future research should prioritize these studies for improved patient outcomes.
Area of Science:
- Oncology
- Nuclear Medicine
Background:
- Prostate-specific membrane antigen (PSMA) is a key target in advanced prostate cancer.
- Radioligand therapy (RLT) offers a targeted approach for treating PSMA-positive cancers.
More Related Videos
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Related Concept Videos
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET